These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36198215)

  • 1. Preclinical characterization of a Fab-like CD3/CLDN18.2 XFab® bispecific antibody against solid tumors.
    Xu G; Qian N; Liu Y; Li H; Yang C; Wang J; Wang F; Chen L; Bai G; Xu Q; Pan X; Gao X
    Immunobiology; 2022 Nov; 227(6):152283. PubMed ID: 36198215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.
    Zhu G; Foletti D; Liu X; Ding S; Melton Witt J; Hasa-Moreno A; Rickert M; Holz C; Aschenbrenner L; Yang AH; Kraynov E; Evering W; Obert L; Lee C; Sai T; Mistry T; Lindquist KC; Van Blarcom T; Strop P; Chaparro-Riggers J; Liu SH
    Sci Rep; 2019 Jun; 9(1):8420. PubMed ID: 31182754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.
    Gao J; Wang Z; Jiang W; Zhang Y; Meng Z; Niu Y; Sheng Z; Chen C; Liu X; Chen X; Liu C; Jia K; Zhang C; Liao H; Jung J; Sung E; Chung H; Zhang JZ; Zhu AX; Shen L
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy.
    Ma Z; Zhou Z; Duan W; Yao G; Sheng S; Zong S; Zhang X; Li C; Liu Y; Ou F; Dahar MR; Huang Y; Yu L
    Cancer Immunol Immunother; 2024 Mar; 73(5):82. PubMed ID: 38554200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer.
    Xu Y; Fu J; Henderson M; Lee F; Jurcak N; Henn A; Wahl J; Shao Y; Wang J; Lyman M; Funes V; Espinoza B; Zhang R; Washington I; Chen SY; Zlomke H; Wang J; Niu N; Li P; Meng F; Burns W; Friedrich M; Stienen S; Bailis JM; Zheng L
    Gastroenterology; 2023 Nov; 165(5):1219-1232. PubMed ID: 37507075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function.
    Yue J; Shao S; Zhou J; Luo W; Xu Y; Zhang Q; Jiang J; Zhu MM
    Invest New Drugs; 2024 Feb; 42(1):106-115. PubMed ID: 38198061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.
    Chervin AS; Stone JD; Konieczna I; Calabrese KM; Wang N; Haribhai D; Dong F; White MK; Rodriguez LE; Bukofzer GT; Ellis PA; Cosgrove C; Hecquet C; Clarin JD; Palma JP; Reilly EB
    Mol Cancer Ther; 2023 Aug; 22(8):903-912. PubMed ID: 37294945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137.
    Kamikawa T; Kimura N; Ishii S; Muraoka M; Kodama T; Taniguchi K; Yoshimoto M; Miura-Okuda M; Uchikawa R; Kato C; Shinozuka J; Akai S; Naoi S; Tomioka N; Nagaya N; Pang CL; Garvita G; Feng S; Shimada M; Kamata-Sakurai M; Aburatani H; Kitazawa T; Igawa T
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39401967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning.
    Haber L; Olson K; Kelly MP; Crawford A; DiLillo DJ; Tavaré R; Ullman E; Mao S; Canova L; Sineshchekova O; Finney J; Pawashe A; Patel S; McKay R; Rizvi S; Damko E; Chiu D; Vazzana K; Ram P; Mohrs K; D'Orvilliers A; Xiao J; Makonnen S; Hickey C; Arnold C; Giurleo J; Chen YP; Thwaites C; Dudgeon D; Bray K; Rafique A; Huang T; Delfino F; Hermann A; Kirshner JR; Retter MW; Babb R; MacDonald D; Chen G; Olson WC; Thurston G; Davis S; Lin JC; Smith E
    Sci Rep; 2021 Jul; 11(1):14397. PubMed ID: 34257348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting.
    Zhou KI; Strickler JH; Chen H
    J Hematol Oncol; 2024 Aug; 17(1):73. PubMed ID: 39183320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy.
    Liang J; Zhang H; Huang Y; Fan L; Li F; Li M; Yan Y; Zhang J; Li Z; Yang X
    Cancer Manag Res; 2021; 13():6977-6987. PubMed ID: 34522140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors.
    Patrick TA; Kranz DM; Zachary JF; Roy EJ
    Int J Cancer; 1998 Nov; 78(4):470-9. PubMed ID: 9797136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
    Löffler A; Kufer P; Lutterbüse R; Zettl F; Daniel PT; Schwenkenbecher JM; Riethmüller G; Dörken B; Bargou RC
    Blood; 2000 Mar; 95(6):2098-103. PubMed ID: 10706880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody.
    Huang L; Xie K; Li H; Wang R; Xu X; Chen K; Gu H; Fang J
    Drug Des Devel Ther; 2020; 14():3201-3214. PubMed ID: 32982167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
    Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
    Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
    Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models.
    Sandker GGW; Middelburg J; Wilbrink E; Molkenboer-Kuenen J; Aarntzen E; van Hall T; Heskamp S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model.
    Mandikian D; Takahashi N; Lo AA; Li J; Eastham-Anderson J; Slaga D; Ho J; Hristopoulos M; Clark R; Totpal K; Lin K; Joseph SB; Dennis MS; Prabhu S; Junttila TT; Boswell CA
    Mol Cancer Ther; 2018 Apr; 17(4):776-785. PubMed ID: 29339550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.